Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES

v3.23.1
ACCRUED EXPENSES
3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

10. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

 

 

March 31,
2023

 

 

December 31,
2022

 

 

 

 

 

 

 

 

Accrued pre-clinical and clinical costs

 

$

4,074,713

 

 

$

2,137,317

 

Accrued product development costs

 

 

409,691

 

 

 

247,500

 

Accrued compensation

 

 

826,703

 

 

 

2,224,951

 

Accrued administrative costs

 

 

143,175

 

 

 

473,376

 

Accrued interest

 

 

1,014,020

 

 

 

916,108

 

Total

 

$

6,468,302

 

 

$

5,999,252